Soleno Therapeutics recently highlighted that 2025 was a transformational year, pointing to strong preliminary revenue from the launch of its rare-disease drug VYKAT XR and plans to release full ...

Soleno Therapeutics (SLNO) jumped nearly 9% after management described 2025 as a transformational year, pointing to early VYKAT XR revenue, upcoming full financial results and a busy investor ...

About PWSPrader-Willi syndrome (PWS) is a rare genetic neurodevelopmental disorder caused by an abnormality in the gene expression on chromosome 15. The Prader-Willi Syndrome Association USA estimates ...

REDWOOD CITY, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, ...

Soleno Therapeutics announced preliminary financial results for Q2 2025, forecasting $31-$33 million in net revenue and reporting significant cash assets. Soleno Therapeutics, Inc. announced ...

Soleno Therapeutics Inc. (NASDAQ:SLNO) is one of the best performing mid cap stocks so far in 2025. On July 10, Soleno Therapeutics announced that the sales of its new Prader-Willi disease drug, ...

Shares of Soleno Therapeutics (NASDAQ:SLNO) fell on Wednesday after a federal database indicated that a 17-year-old male treated with the company’s recently launched rare disease therapy Vykat XR had ...

REDWOOD CITY, Calif., July 01, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, ...

In this article, we will be taking a look at the 13 Most Oversold Healthcare Stocks So Far in 2025. Soleno Therapeutics, Inc. is one of them. Soleno Therapeutics, Inc. (NASDAQ:SLNO) tops our list for ...

Revenue, net, from the sale of VYKAT XR for the three months ended September 30, 2025 was $66.0 million and the Company achieved profitability with positive net income of $26.0 million for the third ...

Announced submission and validation of Marketing Authorization Application (MAA) submission to the European Medicines Agency (EMA) seeking marketing approval of DCCR (marketed in the U.S. as VYKAT XR) ...